Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial
Main finding · AGV (least squares mean)Result — go to the resultDifference 2.74 cm/yearAuthors' conclusion
In this prospective trial, the robust growth and anthropometric results suggest that by continuously relieving the pre-hypertrophic block in achondroplasia, navepegritide may make the growth plate more responsive to the strong complementary effect of lonapegsomatropin.
Study context
- Population
- Children with achondroplasia aged 2 to 11
- Participants
- 21 children
- Exposure
- Weekly navepegritide plus lonapegsomatropin vs navepegritide monotherapy
- Outcome
- Annualized growth velocity (AGV) vs AGV with navepegritide monotherapy in the ApproaCH trial
- Follow-up
- Week 52
Methodological detailsprospective, external comparison with matched navepegritide monotherapy (ApproaCH trial)
- Prospective
- External comparison with matched navepegritide monotherapy (ApproaCH trial)
Main finding
AGV (least squares mean)
Difference
2.74 cm/year
P < 0.0001
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | TN | NE |
|---|---|---|
| Observed mean AGV and change from baseline · week 52cm/year | 8.80 | 8.42 |
| Increase from baseline | +3.89 cm/year (P = .0015) | — not stated in the abstract |
| Increase from navepegritide-treated baseline | — not stated in the abstract | +3.28 cm/year (P < .0001) |
| Arm span and body proportionality | +9.4 cm | +7.9 cm |
— not stated in the abstract
Arm span and body proportionality
- Improvement in body proportionality observed; arm span gains in line with gains in height
Safety
- Treatments were well-tolerated with generally mild adverse events
- No treatment discontinuations
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial. Eur J Endocrinol. Published 18 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →